Gut microbiota and its roles in the pathogenesis and therapy of endocrine system diseases.

Fecal bacteria transplantation Gut microbiome Internal system diseases Microbiology Probiotic treatment

Journal

Microbiological research
ISSN: 1618-0623
Titre abrégé: Microbiol Res
Pays: Germany
ID NLM: 9437794

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 08 09 2022
accepted: 15 12 2022
pubmed: 22 12 2022
medline: 25 1 2023
entrez: 21 12 2022
Statut: ppublish

Résumé

A new field of microbial research is the relationship between microorganisms and multicellular hosts. It is known that gut microbes can cause various endocrine system diseases, such as diabetes and thyroid disease. Changes in the composition or structure and the metabolites of gut microbes may cause gastrointestinal disorders, including ulcers or intestinal perforation and other inflammatory and autoimmune diseases. In recent years, reports on the interactions between intestinal microorganisms and endocrine system diseases have been increasingly documented. In the meantime, the treatment based on gut microbiome has also been paid much attention. For example, fecal microbiota transplantation is found to have a therapeutic effect on many diseases. As such, understanding the gut microbiota-endocrine system interactions is of great significance for the theranostic of endocrine system diseases. Herein, we summarize the relations of gut microbiome with endocrine system diseases, and discuss the potentials of regulating gut microbiome in treating those diseases. In addition, the concerns and possible solutions regarding the gut microbiome-based therapy are discussed.

Identifiants

pubmed: 36542917
pii: S0944-5013(22)00331-7
doi: 10.1016/j.micres.2022.127291
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

127291

Informations de copyright

Copyright © 2022 Elsevier GmbH. All rights reserved.

Auteurs

Zhuoxuan Wu (Z)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.

Erkang Tian (E)

Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.

Yuyang Chen (Y)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.

Zaiquan Dong (Z)

Mental Health Center of West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: zaiquandong@wchscu.cn.

Qiang Peng (Q)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China. Electronic address: qiangpengzz@scu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH